Meta-Analysis of Incidence and Risk of Hypomagnesemia with Cetuximab for Advanced CancerCao Y.a · Liao C.a · Tan A.b · Liu L.a · Gao F.a
Departments of aColorectal and Anal Surgery and bUrology, First Affiliated Hospital, Guangxi Medical University, Nanning,PR China
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Cetuximab is often used in patients with colorectal cancer, head and neck cancer, and other cancers. Hypomagnesemia is a major adverse event that was often ignored in studies. The aim of this meta-analysis is to gain a better understanding of the overall incidence and risk of hypomagnesemia in patients who received cetuximab-based therapy. Methods: Databases, including Pubmed, EMBASE, The Cochrane Library, American Society of Clinical Oncology (2000–2008), and Web of Science, were searched to identify relevant studies. Eligible studies were prospective phase II/III clinical trials of patients with cancer assigned cetuximab at a dose of 400 mg/m2 i.v. on day 1 and 250 mg/m2 weekly thereafter. The primary endpoint was incidence of hypomagnesemia. Results: Nineteen clinical reports were identified which included a total of 4,559 patients available for analysis, with 3,081 patients assigned cetuximab-based treatment. This result showed a high incidence of grade 3 and 4 hypomagnesemia (5.6%; 95% CI = 3.0–10.2) and a high incidence of all-grade hypomagnesemia associated with cetuximab-based therapy for advanced cancer (36.7%; 95% CI = 22–54.4). Compared with non-cetuximab therapy, cetuximab-based therapy has a higher risk of grade 3 and 4 hypomagnesemia (4.75; 95% CI = 3.661–6.18) and all-grade hypomagnesemia (4.75; 95% CI = 3.661–6.18). Conclusion: Cetuximab-based therapy is associated with a significant risk of hypomagnesemia. Early monitoring and effective management of hypomagnesemia are important for patients that received cetuximab-based therapy.
© 2010 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.